GT Biopharma Files 8-K on Agreements and Equity Sales
Ticker: GTBP · Form: 8-K · Filed: Feb 26, 2025 · CIK: 109657
Sentiment: neutral
Topics: material-agreement, equity-sale, financials
TL;DR
GT Biopharma filed an 8-K detailing new agreements and equity sales, plus financial docs.
AI Summary
GT Biopharma, Inc. filed an 8-K on February 25, 2025, reporting on the entry into a material definitive agreement and unregistered sales of equity securities. The filing also includes financial statements and exhibits. The company was formerly known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/.
Why It Matters
This filing provides crucial updates on GT Biopharma's material agreements and equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered equity sales, which can carry inherent risks and require further investigation into the specifics.
Key Players & Entities
- GT Biopharma, Inc. (company) — Registrant
- OXIS INTERNATIONAL INC (company) — Former Company Name
- DDI PHARMACEUTICALS INC (company) — Former Company Name
- DIAGNOSTIC DATA INC /DE/ (company) — Former Company Name
- February 25, 2025 (date) — Date of Report
FAQ
What is the nature of the material definitive agreement entered into by GT Biopharma, Inc. on February 25, 2025?
The filing indicates an 'Entry into a Material Definitive Agreement' as an item information, but the specific details of the agreement are not provided in the provided text.
What type of equity securities were sold in the unregistered sales reported by GT Biopharma, Inc.?
The filing lists 'Unregistered Sales of Equity Securities' as an item information, but the specific type and details of the securities sold are not detailed in the provided text.
What are the key financial statements and exhibits included in this 8-K filing?
The filing mentions 'Financial Statements and Exhibits' as an item information, but the specific content of these documents is not detailed in the provided text.
When did GT Biopharma, Inc. change its name from OXIS INTERNATIONAL INC?
The filing states the date of name change from OXIS INTERNATIONAL INC was 19940916.
What is GT Biopharma, Inc.'s Standard Industrial Classification (SIC) code?
GT Biopharma, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 26, 2025 regarding GT Biopharma, Inc. (GTBP).